Fig. 2: Serum CXCL13 differentially expressed in iMCD compared to clinicopathologically overlapping diseases.
From: CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
a Spearman rank correlation test of log2 CXCL13 against platelets in iMCD (n = 88) at the time of sample draw. There was no discernable relationship (R = −0.015, p = 0.89). b Box plots showing the log2 normalized relative fluorescent unit (RFU) concentrations of CXCL13 in iMCD patients with hyaline vascular (n = 26), mixed (n = 40), and plasmacytic (n = 21) histopathology. Analysis of variance followed by a two-tailed post hoc t-test with Bonferroni adjustment was used to test for differences according to histopathological subtype There was no difference between histopathological subtypes (hyaline vascular vs mixed histopathology, p = 0.06; plasmacytic vs hyaline vascular, p = 0.92; and plasmacytic vs mixed, p = 0.07. c Box plots showing the log2 normalized RFU concentrations of CXCL13 in iMCD compared to the related disorders and healthy donors. iMCD (n = 88) differed from each HHV8-MCD (n = 20), RA (n = 20), HL (n = 20), and healthy (n = 42). Statistical significance of disease status was determined with a linear regression model with age, sex, and CRP as covariates, and a two-tailed Wald test was used to test pairwise differences with iMCD, with multiple comparisons Bonferroni corrected (RA: p = 5.6 × 10−4; HL: p = 0.03; HHV8-MCD: p = 0.003; healthy: p = 3.3 × 10−7). d Pearson correlation test demonstrating a strong linear correlation between log2(CXCL13) as measured by the SomaSCAN multiplex DNA-aptamer assay and by an ELISA immunoassay (n = 66) R = 0.93; 95% confidence interval: 0.89–0.96, p = 1.7 × 10−29). Box plots include a center line (median), box limits (upper and lower quartiles), whiskers (1.5x interquartile range), and all data points. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.
